New imatinib variant tested for CML: could it be better?
NCT ID NCT05623774
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested a new drug called IkT-001Pro in 64 healthy adults aged 18 to 55. The goal was to see if it works like the standard CML drug imatinib in the body. Participants took single doses of both drugs at different times to compare how they are absorbed and processed. The study also checked for safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IkT-001Pro (a new form of imatinib)
What this could lead to
If successful, this could lead to a new version of imatinib that may be easier for patients to take or have fewer side effects.
What could go wrong
This is an early Phase 1 study in healthy volunteers, not patients. It only checks if the drug behaves similarly in the body, not if it actually treats CML. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Tempe, Arizona, 85283, United States